NEW YORK (GenomeWeb) ­­– Vermillion reported after the close of the market on Thursday an 89 percent jump in its first quarter revenues

For the three months ended Sept, 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $623,000 from $330,000 in the year-ago quarter.

Product revenues were $581,000, up from $330,000 in Q3 2015. Service revenues from the company's Aspira IVD business was $42,000. Vermillion had no service revenues in Q3 2015 as Aspira IVD was not yet operating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.